These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8882026)

  • 21. Evidence for immunostimulatory effects of intramuscular gold in patients with rheumatoid arthritis: correlation with skin reactions.
    Ernestam S; Lampa J; Rogberg S; Rönnelid J; Klareskog L; Hafström I
    J Rheumatol; 2003 Aug; 30(8):1748-55. PubMed ID: 12913930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
    Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
    J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.
    Fathi NH; Mitros F; Hoffman J; Straniero N; Labreque D; Koehnke R; Furst DE
    J Rheumatol; 2002 Oct; 29(10):2092-8. PubMed ID: 12375317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis.
    Fuchs HA
    J Rheumatol; 1993 Nov; 20(11):1863-6. PubMed ID: 7905924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of the state of patients with rheumatoid arthritis using a personal computer].
    Hirohata S; Kawashima C; Shinohara S; Sawada T; Nishioka Y; Tohma S; Kisaki T; Inoue T; Iwamoto S; Ito K
    Ryumachi; 1993 Apr; 33(2):131-41. PubMed ID: 8316903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
    Ward MM; Fries JF
    J Rheumatol; 1998 Mar; 25(3):408-16. PubMed ID: 9517756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alkaline phosphatase isoenzyme activities in rheumatoid arthritis: hepatobiliary enzyme dissociation and relation to disease activity.
    Aida S
    Ann Rheum Dis; 1993 Jul; 52(7):511-6. PubMed ID: 8102225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of a rheumatoid arthritis records-based index of severity.
    Ting G; Schneeweiss S; Katz JN; Weinblatt ME; Cabral D; Scranton RE; Solomon DH
    J Rheumatol; 2005 Sep; 32(9):1679-87. PubMed ID: 16142860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM; Fransen J; van Riel PL
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X; Nordström D; Rodriguez M; Rubbert A; Sarzi-Puttini P; Wouters JM; Woolley JM; Wright N; Lawrence C; Appleton B
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report.
    Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K
    J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.
    Martin L; Sitar DS; Chalmers IM; Hunter T
    J Rheumatol; 1985 Apr; 12(2):270-3. PubMed ID: 2863375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.